ArticleCancer medicine2026
Oncologic Outcomes of Cytoreductive Radical Prostatectomy in Patients With Synchronous Metastatic Castration-Sensitive Prostate Cancer: A Retrospective Analysis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLocal therapy for metastatic castration-sensitive prostate cancer (mCSPC) remains controversial. This study aimed to assess the feasibility, safety, and oncologic outcomes of cytoreductive radical prostatectomy (cRP) in patients with synchronous mCSPC, with a particular focus on pathological findings.
methodWe retrospectively analyzed 61 patients with mCSPC who underwent cRP following neoadjuvant androgen deprivation therapy (ADT). Clinical, perioperative, and pathological parameters were reviewed. Survival outcomes were assessed in relation to biopsy Gleason grade (GG), metastatic burden, PSA dynamics, and pathological treatment effect (pTE).
resultsThe 5-year CRPC-free survival and cancer-specific survival (CSS) rates were 50.8% and 77.0%, respectively. Biopsy GG 5 was associated with adverse outcomes, whereas pTE grade ≥ 2 was significantly associated with favorable outcomes, including improved CSS. Biopsy GG 5 was the sole preoperative factor associated with pTE. The rate of major perioperative complications (Clavien-Dindo grade ≥ 3) was 1.6%, underscoring the safety of cRP in this setting.
conclusionCytoreductive radical prostatectomy (cRP) appears to be a feasible and safe local treatment option in selected patients with mCSPC. In addition to cytoreductive benefit, cRP provides critical pathological information-particularly pTE-that correlates strongly with survival outcomes but cannot be predicted preoperatively. These findings support the incorporation of cRP as a diagnostic and therapeutic component within a multimodal treatment strategy for mCSPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.